Nautilus Biotechnology Inc (NAUT) - Net Assets
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has net assets worth $169.14 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($200.91 Million) and total liabilities ($31.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Nautilus Biotechnology Inc balance sheet assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $169.14 Million |
| % of Total Assets | 84.18% |
| Annual Growth Rate | 86.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 166.42 |
Nautilus Biotechnology Inc - Net Assets Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Check NAUT intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual net assets of Nautilus Biotechnology Inc from 2018 to 2024. For live valuation and market cap data, see Nautilus Biotechnology Inc (NAUT) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $208.73 Million | -21.34% |
| 2023-12-31 | $265.35 Million | -15.74% |
| 2022-12-31 | $314.92 Million | -13.38% |
| 2021-12-31 | $363.58 Million | +1323.30% |
| 2020-12-31 | $-29.72 Million | -264.64% |
| 2019-12-31 | $18.05 Million | +261.04% |
| 2018-12-31 | $5.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nautilus Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43671.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $13.00K | 0.01% |
| Other Comprehensive Income | $57.00K | 0.03% |
| Other Components | $481.68 Million | 230.77% |
| Total Equity | $208.73 Million | 100.00% |
Nautilus Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Nautilus Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Igis Value Plus Reit Co Ltd
KO:334890
|
$123.41 Million |
|
FinLab AG
F:A7A
|
$123.46 Million |
|
Silk Logistics Holdings Ltd
AU:SLH
|
$123.48 Million |
|
Climb Global Solutions
NASDAQ:CLMB
|
$123.48 Million |
|
Bohae Brewery
KO:000890
|
$123.37 Million |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
$123.33 Million |
|
Century Land Joint Stock Company
VN:CRE
|
$123.32 Million |
|
AMREP Corporation
NYSE:AXR
|
$123.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nautilus Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 265,353,000 to 208,730,000, a change of -56,623,000 (-21.3%).
- Net loss of 70,780,000 reduced equity.
- Share repurchases of 524,000 reduced equity.
- Other comprehensive income increased equity by 312,000.
- Other factors increased equity by 14,369,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-70.78 Million | -33.91% |
| Share Repurchases | $524.00K | -0.25% |
| Other Comprehensive Income | $312.00K | +0.15% |
| Other Changes | $14.37 Million | +6.88% |
| Total Change | $- | -21.34% |
Book Value vs Market Value Analysis
This analysis compares Nautilus Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.59x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.40x to 0.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.70 | $0.98 | x |
| 2019-12-31 | $2.98 | $0.98 | x |
| 2020-12-31 | $-0.90 | $0.98 | x |
| 2021-12-31 | $4.30 | $0.98 | x |
| 2022-12-31 | $2.53 | $0.98 | x |
| 2023-12-31 | $2.12 | $0.98 | x |
| 2024-12-31 | $1.66 | $0.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nautilus Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-33.91%) is below the historical average (1769.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 12532.00% | 0.00% | 0.00x | 29.16x | $626.10 Million |
| 2019 | -53.28% | 0.00% | 0.00x | 1.03x | $-11.42 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.65 Million |
| 2021 | -13.84% | 0.00% | 0.00x | 1.10x | $-86.67 Million |
| 2022 | -18.39% | 0.00% | 0.00x | 1.11x | $-89.42 Million |
| 2023 | -24.00% | 0.00% | 0.00x | 1.15x | $-90.21 Million |
| 2024 | -33.91% | 0.00% | 0.00x | 1.16x | $-91.65 Million |
Industry Comparison
This section compares Nautilus Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nautilus Biotechnology Inc (NAUT) | $169.14 Million | 12532.00% | 0.19x | $123.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more